"As a clinical stage cardiovascular company, with an epigenetics platform, Resverlogix is leading the way in the creation of first-in-class small molecule therapeutics. Our exceptional staff and internationally respected experts are working diligently to safely bring to the market new therapeutics for our future patients. We continue our dedication to delivering concrete performance for our shareholders and diverse stakeholders."
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune diseases, neurodegenerative diseases and diabetes mellitus.
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.